Arthur Ryan Biography and Net Worth

Arthur F. Ryan serves as Independent Director of the Company. In 2008, Mr. Ryan retired as the Chairman of the Board of Prudential Financial, Inc., one of the largest diversified financial institutions in the world. He served as Chief Executive Officer of Prudential until 2007. Prior to joining Prudential in 1994, Mr. Ryan served as President and Chief Operating Officer of Chase Manhattan Bank since 1990. Mr. Ryan managed Chase’s worldwide retail bank between 1984 and 1990. From 2008 to 2013, Mr. Ryan served as a non-executive director of the Royal Bank of Scotland Group plc. From 2009 to 2019, Mr. Ryan served as a director of Citizens Financial Group, Inc., a retail bank holding company that became publicly traded in 2014, and also served as its lead director, chair of the Compensation and Human Resources Committee, and a member of the Nominating and Corporate Governance Committee. Mr. Ryan’s substantial leadership experience as a chief executive officer of leading companies in the banking and insurance industries, and his extensive business experience and financial expertise, led the board to conclude that Mr. Ryan should serve as a director.

What is Arthur F. Ryan's net worth?: The estimated net worth of Arthur F. Ryan is at least $11.45 million as of July 1st, 2024. Mr. Ryan owns 17,882 shares of Regeneron Pharmaceuticals stock worth more than $11,446,983 as of March 26th. This net worth approximation does not reflect any other assets that Mr. Ryan may own. Learn More about Arthur F. Ryan's net worth.
How do I contact Arthur F. Ryan?: The corporate mailing address for Mr. Ryan and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at invest@regeneron.com. Learn More on Arthur F. Ryan's contact information.
Has Arthur F. Ryan been buying or selling shares of Regeneron Pharmaceuticals?: Arthur F. Ryan has not been actively trading shares of Regeneron Pharmaceuticals during the past quarter. Most recently, Arthur F. Ryan sold 100 shares of the business's stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a transaction totalling $105,924.00. Following the completion of the sale, the director now directly owns 17,882 shares of the company's stock, valued at $18,941,329.68. Learn More on Arthur F. Ryan's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 71,241 shares worth more than $71,913,487.25. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

Arthur F. Ryan Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/1/2024	Sell	100	$1,059.24	$105,924.00	17,882
3/1/2024	Sell	100	$982.05	$98,205.00	18,282
2/1/2024	Sell	100	$954.22	$95,422.00	18,382
12/1/2023	Sell	100	$817.30	$81,730.00	18,447
11/7/2023	Sell	100	$827.90	$82,790.00	18,547
8/1/2023	Sell	100	$736.59	$73,659.00	18,647
7/3/2023	Sell	100	$716.88	$71,688.00	18,747
6/1/2023	Sell	100	$735.42	$73,542.00	18,847
4/3/2023	Sell	100	$819.31	$81,931.00	19,047
3/1/2023	Sell	100	$762.50	$76,250.00	19,147
8/4/2022	Sell	10,453	$621.29	$6,494,344.37	18,408
5/2/2022	Sell	100	$650.78	$65,078.00	22,182
4/1/2022	Sell	100	$692.81	$69,281.00	22,282
2/1/2022	Sell	100	$607.14	$60,714.00
12/1/2021	Sell	100	$637.53	$63,753.00
10/1/2021	Sell	100	$569.49	$56,949.00
7/1/2021	Sell	100	$564.50	$56,450.00	23,589
6/14/2021	Sell	100	$524.76	$52,476.00	23,673
12/1/2020	Sell	100	$520.48	$52,048.00	23,741
11/2/2020	Sell	100	$548.54	$54,854.00	27,323
8/3/2020	Sell	100	$641.93	$64,193.00	28,640
6/1/2020	Sell	100	$603.23	$60,323.00	28,838
5/1/2020	Sell	100	$520.37	$52,037.00	28,931
4/1/2020	Sell	100	$483.85	$48,385.00	29,141
3/30/2020	Sell	100	$466.69	$46,669.00	29,141
11/15/2016	Sell	2,000	$429.34	$858,680.00	36,500
5/24/2016	Sell	1,000	$396.64	$396,640.00	40,500
5/31/2013	Sell	2,500	$249.55	$623,875.00
11/1/2012	Sell	10,000	$145.57	$1,455,700.00

See Full Table

Arthur F. Ryan Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $640.14

$629.02

$644.00

50 Day Range

MA: $687.18

$634.14

$744.83

2 Week Range

Now: $640.14

$630.62

$1,211.20

Volume

1,251,227 shs

Average Volume

639,898 shs

Market Capitalization

$69.98 billion

P/E Ratio

16.72

Dividend Yield

0.13%

Beta

0.27